Designed for high-volume manufacturing and flexibility
At 136,000 sq ft, the iCTC is among the largest cell therapy manufacturing facilities in existence. It currently supplies commercial product and investigational TIL cell therapies for Iovance clinical trials.
The current capacity of iCTC is expected to meet the demand for thousands of patients per year with multiple types of cancer. The flexible design can also accommodate new cancer tumor types, as well as next-generation TIL products and manufacturing processes. Capacity expansion is currently underway at iCTC to supply TIL cell therapies for more than 5,000 patients annually in the next few years.
A vibrant hub of cell therapy innovation
iCTC is strategically located in Pennsylvania—the birthplace of cell and gene therapies and the home of leading academic institutions active in research. It is also the emerging hub for innovative biotechnology companies and contract development and manufacturing organizations.
The proximity of iCTC to multiple airports facilitates delivery of TIL cell therapies to treatment centers. The iCTC is expected to cover logistics and delivery of TIL cell therapies in North America, Europe and other markets.
Key highlights
- Core suites optimized for high-volume manufacturing (Gen 2 and Gen 3 processes)
- Flexible suites support a growing pipeline
- Leadership in Energy and Environmental Design (LEED) certified
- Integrated quality control, supply chain and IT systems
- Tax savings under Pennsylvania’s Keystone Opportunity Improvement Zone (KOIZ)